We are live on ! Find out more
COLL icon

Collegium Pharmaceutical

25.55 USD
+0.12
0.47%
At close Updated Nov 17, 4:00 PM EST
Pre-market
After hours
25.55
0.00
0%
1 day
0.47%
5 days
5.88%
1 month
11.04%
3 months
-8.98%
6 months
-24.07%
Year to date
-43.88%
1 year
-43.65%
5 years
30.62%
10 years
55.6%
 

About: Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.

Employees: 423

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 26.3%
Neutral 57.9%
Negative 15.8%
Positive
Zacks Investment Research
14 hours ago
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
Positive
Zacks Investment Research
7 days ago
Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade
Neutral
Seeking Alpha
10 days ago
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive VP & CFO Conference Call Participants Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Alexander Xenakis - Truist Securities, Inc., Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2026 Earnings Conference Call.
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript
Positive
Zacks Investment Research
12 days ago
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates
Positive
Zacks Investment Research
12 days ago
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics
The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics
Neutral
MarketBeat
12 days ago
Collegium Pharmaceutical Q3 Earnings Call Highlights
Collegium Pharmaceutical NASDAQ: COLL reported record third-quarter 2026 revenue as growth in its attention-deficit/hyperactivity disorder portfolio helped offset declining sales of pain medicines. The company reaffirmed its full-year outlook, though quarterly earnings fell from a year earlier.
Collegium Pharmaceutical Q3 Earnings Call Highlights
Neutral
GlobeNewsWire
12 days ago
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS ® Quarterly Net Revenue of $26.5 Million in First Full Quarter of Sales Under Collegium Ownership – – Generated Quarterly Pain Portfolio Net Revenues of $138.0 Million – – Announced $50 Million Accelerated Share Repurchase in Q3'26 – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass.
Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance
Neutral
Zacks Investment Research
13 days ago
COLL or SDZNY: Which Is the Better Value Stock Right Now?
Investors interested in stocks from the Medical - Drugs sector have probably already heard of Collegium Pharmaceutical (COLL) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two stocks offers value investors a better bang for their buck right now?
COLL or SDZNY: Which Is the Better Value Stock Right Now?
Negative
Zacks Investment Research
19 days ago
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Collegium Pharmaceutical (COLL) Q3 Earnings Expected to Decline
Neutral
GlobeNewsWire
19 days ago
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families New multi-year partnership combines youth coach training, an annual Sports for All Summit, and sensory inclusion programs to support neurodivergent children and families
Collegium Pharmaceutical and Boston Legacy FC Expand Their Partnership Beyond Matchday to Communities Across Massachusetts
Price charts implemented using Lightweight Charts™